Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.
Chan-Yuan WuQian WangJian ShiXiu-Ying ZhangRong DuJie-Ruo GuQi-Huan LiuJiao YuJia-Wei XuYan-Jie ZhangHao ZhuMeng-Tao LiXiao-Feng ZengPublished in: Rheumatology and therapy (2023)
EU PAS Register: EUPAS34213.